Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.12), $0.26 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $28.94 million versus the consensus estimate of $10.65 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.